Envue Medical Expands AI Navigation Platform With Robotic Prototype

ENvue Medical, Inc. (NASDAQ: FEED ) announced Thursday the development and demonstration of the prototype of ENvue Drive. It is an investigational robot-assisted platform designed to combine artificial intelligence, real-time electromagnetic navigation, and robotic-assisted procedural execution into a single bedside workflow. Read Also: EXCLUSIVE: ENvue Medical Says Health System Renewal Extends Platform Adoption Through 2028 Prototype Combines AI, Navigation And Robotics The company said the prototype marks a key milestone in its strategy to integrate navigation, AI, and automation into clinical procedures.

The prototype demonstration paired ENvue’s proprietary AI navigation software, Ask Oscar, with robotic-assisted tube advancement to simulate a bedside enteral feeding tube placement procedure. According to the company, ENvue Drive identified anatomical pathways, detected deviations from the intended trajectory, provided corrective guidance, and assisted with advancing the feeding tube to the target location in the small intestine under clinician supervision. ENvue emphasized that the system is designed to support clinicians rather than replace them, with the healthcare professional maintaining full control throughout the procedure. S.

for real-time electromagnetic guidance during enteral feeding tube placement. ENvue recently introduced Ask Oscar, its AI-based education and training platform, and said it is now expanding that technology to support future procedural guidance and robotic-assisted execution. Platform Designed For Future Clinical Applications ENvue said the platform architecture was designed from the outset to support both enteral and vascular access procedures, consistent with its previously announced 2025 initiative.

While the latest demonstration focused on enteral feeding tube advancement, the company said it intends to extend the platform to additional clinical applications, including vascular access, neonatal care, urinary access, and other high-volume bedside workflows. S. Food and Drug Administration for review. The system has not been cleared or approved for clinical use.

49 during premarket trading on Thursday, according to Pro data. Read Also: Futurum's Shay Boloor Explains Why Nvidia, AMD, Apple and Broadcom All Depend on TSMC: 'Every Token Ultimately Pays an Invisible Royalty' Image via Shutterstock